12:57 PM EDT, 04/01/2024 (MT Newswires) -- Zai Lab ( ZLAB ) partner Bristol-Myers Squibb ( BMY ) reported that its phase 3 study of Krazati, or adagrasib, in patients with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRAS mutation met the primary endpoint of progression-free survival and the key secondary endpoint of overall response rate.

The study remains ongoing to assess the additional key secondary endpoint of overall survival, the company said, adding that Krazati had no new safety signals and the safety data was consistent with the known safety profile.

Zai Lab ( ZLAB ) said it expects to submit a new drug application for adagrasib to the National Medical Products Association for KRASG12C mutated NSCLC in second or later line treatment in China this year.

Price: 53.17, Change: -1.06, Percent Change: -1.95